Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21632249 | 0.77 | PTGFR (0.46) | NR3C2NR3C1 | |
| SCHEMBL4490249 | 0.75 | NR3C2 (0.51) | NR3C2NR3C1 | |
| SCHEMBL21656201 | 0.75 | NR3C1 (0.41) | NR3C2NR3C1 | |
| SCHEMBL1634784 | 0.75 | NR3C2 (0.53) | NR3C2NR3C1 | |
| SCHEMBL31445827 | 0.74 | NR3C2 (0.49) | NR3C2NR3C1 | |
| SCHEMBL28918682 | 0.74 | MEN1 (0.40) | NR3C2 | |
| SCHEMBL4309317 | 0.73 | NR3C2 (0.54) | NR3C2NR3C1 | |
| SCHEMBL16579352 | 0.73 | NR3C2 (0.47) | NR3C2NR3C1 | |
| SCHEMBL30087602 | 0.73 | NR3C2 (0.45) | NR3C2NR3C1 | |
| SCHEMBL21656314 | 0.72 | GAA (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213089-A1 | INHIBITING CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB) | FORMA THERAPEUTICS, INC. | 2022-07-07 | — | — | US | disclosed |
| EP-3937940-A1 | INHIBITING CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB) | Forma Therapeutics, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| WO-2020190791-A1 | INHIBITING CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB) | FORMA THERAPEUTICS, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213089-A1 | INHIBITING CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB) | CREBBP, CREB1, EP300 | NR3C2 830/4885NR3C1 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.